Sunday, November 15, 2020

BIOCON | Stock to Buy | Price Outlook



Stock/Share Price: 434

➽ In this article we will discuss recent development in the StockShare of BIOCON in the Stock Market

Recent Key Strengths

Consistent Highest Return Stocks over Five Years - Nifty500

Growth in Net Profit with increasing Profit Margin (QoQ)

Company with Low Debt

Increasing Revenue every quarter for the past 2 quarters

Increasing profits every quarter for the past 2 quarters

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Company with Zero Promoter Pledge

FII / FPI or Institutions increasing their shareholding

Strong Momentum: Price above short, medium and long term moving averages

Recent Weaknesses

MFs decreased their shareholding last quarter

Decline in Quarterly Net Profit with falling Profit Margin (YoY)

Declining Net Cash Flow : Companies not able to generate net cash

Technical Chart 

Stock is in strong uptrend making higher high and higher low. The stock after correcting from the level of 460 is available at 434. 

Long position can bee made in the stock for the upside level of 484 in the short term . The stock can also be bought for long term portfolio. One of the most return generating pharma company for the investors.

Recent Valuation Summary

Dividend Summary

For the year ending March 2020 Biocon has declared an equity dividend of 10.00% amounting to Rs 0.5 per share. At the current share price of Rs 434.35 this results in a dividend yield of 0.12%.

The company has a good dividend track report and has consistently declared dividends for the last 5 years.

Recent Financial Summary

Key Balance Sheet Summary

Thanks for your Precious Time.

Finvest Online
Telegram  :

r- The information on this blog are based on my personal opinion and experience, it should not be considered professional financial investment advice and in no way it should be considered as a tip. We does not take any compensation of any kind whatsoever from any reader,user and company that are mention on this website.We are not SEBI registered financial advisor or analyst.

No comments:

Post a Comment